Reslink Exhaled Nitric Oxide Analyzer

The WLD801 is a non-invasive analyzer that measures exhaled nitric oxide (FeNO) levels to assess airway inflammation in respiratory conditions such as asthma and allergic rhinitis. It provides rapid, objective diagnostic support for clinicians in pulmonology and allergy departments. The device delivers quantitative results with high sensitivity and specificity for patient management.

Portable breath analyzer for measuring fractional exhaled nitric oxide (FeNO) levels, used in clinical assessment of airway inflammation and asthma management. The device provides rapid, non-invasive diagnostic testing suitable for point-of-care and home-based monitoring applications.

A home-use breath analyzer designed for patients with chronic respiratory diseases and susceptible populations, featuring a mobile application and detection diagnostic treatment service card. It offers FeNO/FnNO self-testing capabilities using hospital-grade gas detection technology with interconnected diagnostic services, enabling chronic respiratory disease patients to reduce acute exacerbations and emergency hospitalization, and susceptible populations to reduce disease development risk.

A home-use breath analyzer designed for chronic respiratory disease patients and susceptible populations, featuring mobile application integration and diagnostic service support. The NA series enables FeNO/FnNO self-testing for individual risk assessment and management, reducing the incidence of acute exacerbations and preventing the development of chronic respiratory diseases.

A multi-molecular breath analysis system that detects NO, H2S, H2, CH4, CO, CO2, and O2 for simultaneous assessment of intestinal inflammation and microbiota status. It features olfactory AI and multimodal diagnostic capabilities. The device is designed for use in gastroenterology, pediatrics, physical examinations, and allergy departments, and is indicated for conditions including irritable bowel syndrome, inflammatory bowel disease, colorectal cancer, Helicobacter pylori infection, functional dyspepsia, liver disease, and allergic rhinitis/asthma.

A breath testing device designed for clinics, pharmacies, health screening centers, nursing homes, and community settings. It uses the same gas detection technology as hospital systems with interconnected diagnostic and treatment services, enabling hierarchical diagnosis and treatment of chronic respiratory diseases and cardiopulmonary health screening. It provides FeNO/CaNO/FeCO/FnNO testing for cough and asthma patients to optimize medication selection, reduce acute exacerbations and emergency hospitalization, and for susceptible populations for risk warning and disease prevention.

A multi-molecular, multi-site, multi-parameter breath analysis system for detecting inflammation and related conditions. The CA series includes multiple configurations (CA3478, CA3138, CA4458) that measure various exhaled gases including NO, CO, H2S, CH4, CO2, and O2 in different combinations. It supports online and offline sampling modes with quality control features, and is designed for respiratory, pediatric, ENT, surgical, radiology, and physical examination departments to diagnose conditions such as asthma, COPD, interstitial lung disease, lung cancer, chronic cough, allergic rhinitis, sinusitis, and perioperative pulmonary complications.

A home-use breath analyzer designed for chronic respiratory disease patients and susceptible individuals, equipped with a mobile app and detection and treatment service card. The HA and NA series measure FeNO/FnNO for self-testing to reduce acute exacerbations, emergency hospitalizations, and the risk of disease onset and progression to chronic conditions.

A breath analyzer designed for patients with chronic respiratory diseases and susceptible populations, equipped with a mobile application and detection diagnostic treatment service card. It uses the same gas detection technology as hospital systems with interconnected diagnostic and treatment services, providing FeNO/FnNO self-testing for chronic cough and asthma patients to reduce acute exacerbations and emergency hospitalization, and for susceptible populations to reduce disease onset risk and progression to chronic disease.

A breath analysis device designed for clinics, pharmacies, health check centers, nursing homes, and community settings using the same gas detection technology as hospital systems. The TM series performs FeNO/CaNO/FeCO/FnNO testing for respiratory chronic disease tiered diagnosis and heart-lung health screening, helping optimize drug selection and reduce acute exacerbations, emergency hospitalizations, and lung cancer risk.

A breath analysis device for multi-molecular, multi-site, multi-parameter testing of respiratory and digestive conditions with complications. The CA series includes inflammatory phenotyping breath testing with NO baseline plus CO and H2S optional configurations, supporting online standard, offline, and tidal breath modes. It features breath quality control with standard gas and self-calibration, and is applicable to respiratory, pediatric, otolaryngology, surgery, radiology, and health screening departments for conditions including asthma, COPD, interstitial lung disease, lung cancer, chronic cough, allergic rhinitis, sinusitis, nasal polyps, radiation pneumonitis, and perioperative pulmonary complications.

A home-use breath analyzer designed for chronic respiratory disease patients and susceptible populations, equipped with a mobile application and diagnostic service card. The HA series provides FeNO/FnNO self-testing capability synchronized with hospital-grade diagnostic services, helping reduce acute exacerbations, emergency hospitalization, and disease progression risk.